抄録
Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.
Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.
Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).
Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 371-378 |
| ページ数 | 8 |
| ジャーナル | Anticancer Research |
| 巻 | 35 |
| 発行部数 | 1 |
| 出版物ステータス | 出版済み - 1 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
これを引用
Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. / Hirano, Gen; Makiyama, Akitaka; Makiyama, Chinatsu; Esaki, Taito; Oda, Hisanobu; Uchino, Keita; Komoda, Masato; Tanaka, Risa; Matsushita, Yuzo; Mitsugi, Kenji; Shibata, Yoshihiro; Kumagai, Hozumi; Arita, Shuji; ariyama, hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.
：: Anticancer Research, 巻 35, 番号 1, 01.01.2015, p. 371-378.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan
AU - Hirano, Gen
AU - Makiyama, Akitaka
AU - Makiyama, Chinatsu
AU - Esaki, Taito
AU - Oda, Hisanobu
AU - Uchino, Keita
AU - Komoda, Masato
AU - Tanaka, Risa
AU - Matsushita, Yuzo
AU - Mitsugi, Kenji
AU - Shibata, Yoshihiro
AU - Kumagai, Hozumi
AU - Arita, Shuji
AU - ariyama, hiroshi
AU - Kusaba, Hitoshi
AU - Akashi, Koichi
AU - Baba, Eishi
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.
AB - Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.
UR - http://www.scopus.com/inward/record.url?scp=84920433770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920433770&partnerID=8YFLogxK
M3 - Article
VL - 35
SP - 371
EP - 378
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 1
ER -